Analysts at Jefferies called the approval "highly significant," estimating it could add $2 billion to $3 billion to peak ...
Ambros Therapeutics’ non-opioid bisphosphonate analgesic, already approved in Italy, will soon begin a pivotal test in the ...
Johnson & Johnson, which did not apply for the national priority voucher, was granted the ticket based on results from a ...
Representatives of companies including AbbVie, Eli Lilly, Johnson & Johnson and Merck have voiced concerns about the FDA’s ...
Varegacestat, a gamma secretase inhibitor, significantly improved progression-free survival while also meeting all key ...
Sanofi bought Dren’s DR-0201 program earlier this year for $600 million upfront and is running two Phase I trials in ...
Vyvgart, an FcRn inhibitor already approved for generalized myasthenia gravis, is also being tested in myositis, Sjögren’s ...
Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback